2019
General Predictors and Moderators of Depression Remission: A VAST-D Report
Zisook S, Johnson GR, Tal I, Hicks P, Chen P, Davis L, Thase M, Zhao Y, Vertrees J, Mohamed S. General Predictors and Moderators of Depression Remission: A VAST-D Report. American Journal Of Psychiatry 2019, 176: 348-357. PMID: 30947531, DOI: 10.1176/appi.ajp.2018.18091079.Peer-Reviewed Original ResearchMeSH KeywordsAdultAdverse Childhood ExperiencesAgedAged, 80 and overAntidepressive AgentsAripiprazoleBupropionDepressive Disorder, MajorDrug SubstitutionDrug Therapy, CombinationEmploymentFemaleGriefHumansLife TablesMaleMiddle AgedPrognosisQuality of LifeRemission InductionSeverity of Illness IndexSingle-Blind MethodUnited StatesUnited States Department of Veterans AffairsYoung AdultConceptsNext-step treatmentsRelease bupropionVeterans Health Administration patientsPatients' baseline featuresSingle-blind trialMajor depressive disorderDepression Outcomes studyComplicated grief symptomsAntidepressant treatmentBaseline characteristicsInitial treatmentDepression remissionDepressive disorderRemissionOutcome studiesTreatment selectionTreatment groupsHypomanic symptomsSwitching treatmentClinical imperativePositive mental healthChildhood adversityPatientsMental healthSpecific augmentation
2016
Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis
Smith PH, Weinberger AH, Zhang J, Emme E, Mazure CM, McKee SA. Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis. Nicotine & Tobacco Research 2016, 19: 273-281. PMID: 27613893, PMCID: PMC5939704, DOI: 10.1093/ntr/ntw144.Peer-Reviewed Original ResearchConceptsTransdermal nicotineSmoking cessationBupropion SRComparative efficacyFirst option treatmentSustained release bupropionPlacebo-controlled trialSex differencesCigarette smoking cessationNetwork Meta-AnalysisRelease bupropionCessation pharmacotherapyOption treatmentGeneral community sampleCigarette smokersQuit ratesVarenicline's efficacyPharmacological interventionsVareniclineBupropionNicotine addictionMeta-analysisPlaceboSimilar outcomesSignificant sex differences
2010
Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion
Mazure CM, Toll B, McKee SA, Wu R, O’Malley S. Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion. Drug And Alcohol Dependence 2010, 114: 68-72. PMID: 20832955, PMCID: PMC3016455, DOI: 10.1016/j.drugalcdep.2010.07.024.Peer-Reviewed Original ResearchConceptsMenstrual cycle phaseQuit datePoint prevalence abstinencePremenopausal womenBupropion SRFollicular phaseLuteal phaseAbsence of pharmacotherapySustained release bupropionOpen-label trialCycle phaseMechanism of actionRelease bupropionLabel trialNicotine replacementCessation interventionsOpen trialTreatment completionCessation outcomesContinuous abstinenceQuit dayGonadal hormonesTreatment periodAbstinence outcomesQuit attempts
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply